A rare splice site mutation in the gene encoding glucokinase/hexokinase 4 in a patient with MODY type 2

The article presents a variant of maturity onset diabetes of the young type 2, caused by a rare mutation in the GCK gene. Maturity onset diabetes of the young (MODY) is a hereditary form of diabetes with an autosomal dominant type of inheritance, an onset at a young age, and a primary defect in pancreatic β-cell function. This type of diabetes is different from classical types of diabetes mellitus (DM1 and DM2) in its clinical course, treatment strategies, and prognosis. Clinical manifestations of MODY are heterogeneous and may vary even among members of the same family, i. e., carriers of identical mutations. This phenotypic variation is due to the interaction of mutations with different genetic backgrounds and the influence of environmental factors (e. g., lifestyle). Using next-generation sequencing technology, the c.580–1G>A substitution (IVS5 –1G>A, rs1554335421) located in an acceptor splice site of intron 5 of the GCK gene was found in a proband. The identified variant cosegregated with a pathological phenotype in the examined family members. The GCK gene encodes glucokinase (hexokinase 4), which catalyzes the first step in a large number of glucose metabolic pathways such as glycolysis. Mutations in this gene are the cause of MODY2. The illness is characterized by an insignificant increase in the fasting glucose level, is a well-controlled disease without medication, and has a low prevalence of micro- and macrovascular complications of diabetes. The presented case of MODY2 reveals the clinical significance of a mutation in the splice site of the GCK gene. When nonclassical diabetes mellitus is being diagnosed in young people and pregnant women, genetic testing is needed to verify the diagnosis and to select the optimal treatment method.

human, maturity onset diabetes of the young, MODY2, glucokinase gene, next-generation sequencing, genetic analysis, bioinformatics

1. Abramowicz A., Gos M. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J. Appl. Genet. 2018; 59:253-268. DOI 10.1007/s13353-018-0444-7.

2. Anık A., Çatlı G., Abacı A., Böber E. Maturity-onset diabetes of the young (MODY): an update. J. Pediatr. Endocrinol. Metab. 2015;28: 251-263. DOI 10.1515/jpem-2014-0384.

3. Bonnefond A., Philippe J., Durand E., Dechaume A., Huyvaert M., Montagne L., Marre M., Balkau B., Fajardy I., Vambergue A., Vatin V., Delplanque J., Le Guilcher D., De Graeve F., Lecoeur C., Sand O., Vaxillaire M., Froguel P. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One. 2012;7(6):e37423. DOI 10.1371/journal.pone.0037423.

4. Caetano L.A., Jorge A.A., Malaquias A.C., Trarbach E.B., Queiroz M.S., Nery M., Teles M.G. Incidental mild hyperglycemia in children: two MODY 2 families identified in Brazilian subjects. Arq. Bras. Endocrinol. Metabol. 2012;56(8):519-24. http://dx.doi.org/10.1590/S0004-27302012000800010.

5. Chakera A.J., Carleton V.L., Ellard S., Wong J., Yue D.K., Pinner J., Hattersley A.T., Ross G.P. Antenatal diagnosis of fetal genotype determines if maternal hyperglycemia due to a glucokinase mutation requires treatment. Diabetes Care. 2012;35(9):1832-1834. DOI 10.2337/dc12-0151.

6. Chakera A.J., Spyer G., Vincent N., Ellard S., Hattersley A.T., Dunne F.P. The 0.1 % of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort. Diabetes Care. 2014; 37(5):1230-1236. DOI 10.2337/dc13-2248.

7. Chakera A.J., Steele A.M., Gloyn A.L., Shepherd M.H., Shields B., Ellard S., Hattersley A.T. Recognition and management of individuals with hyperglycemia because of heterozygous glucokinase mutations. Diabetes Care. 2015;38(7):1383-1392. DOI 10.2337/dc14-2769.

8. Edghill E.L., Minton J.A., Groves C.J., Flanagan S.E., Patch A.M., Rubio-Cabezas O., Shepherd M., Lenzen S., McCarthy M.I., Ellard S., Hattersley A.T. Sequencing of candidate genes selected by beta cell experts in monogenic diabetes of unknown aetiology. J. Pancreas – JOP. 2010;11(1):14-17. http://dx.doi.org/10.6092/1590-8577/3864.

9. Esmaeilzadeh H., Bordbar M.R., Dastsooz H., Silawi M., Fard M.A.F., Adib A., Kafashan A., Tabatabaei Z., Sadeghipour F., Faghihi M.A. A novel splice site mutation in WAS gene in patient with Wiskott-Aldrich syndrome and chronic colitis: a case report. BMC Med. Genet. 2018;19(1):123. DOI 10.1186/s12881-018-0647-0.

10. Fajans S.S., Bell G.I., Polonsky K.S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med. 2001;345(13):971-980. DOI 10.1056/NEJMra002168.

11. Igudin E.L., Spirin P.V., Prassolov V.S., Rubtsov P.M., Zubkova N.A., Tyul’pakov A.N., Petryaikina E.E. Functional characterization of two novel splicing mutations of glucokinase gene associated with maturity-onset diabetes of the young type 2 (MODY2). Mol. Biol. 2014;48(2):248-253. DOI 10.1134/S0026893314020071.

12. Inoue M., Sakuraba Y., Motegi H., Kubota N., Toki H., Matsui J., Toyoda Y., Miwa I., Terauchi Y., Kadowaki T., Shigeyama Y., Kasuga M., Adachi T., Fujimoto N., Matsumoto R., Tsuchihashi K., Kagami T., Inoue A., Kaneda H., Ishijima J., Masuya H., Suzuki T., Wakana S., Gondo Y., Minowa O., Shiroishi T., Noda T. A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program. Hum. Mol. Genet. 2004;13(11):1147-1157. DOI 10.1093/hmg/ddh133.

13. Iynedjian P.B. Molecular physiology of mammalian glucokinase. Cell. Mol. Life Sci. 2009;66(1):27-42. DOI 10.1007/s00018-008-8322-9.

14. Jang M.A., Kim Y.E., Kim S.K., Lee M.K., Kim J.W., Ki C.S. Identification and characterization of NF1 splicing mutations in Korean patients with neurofibromatosis type 1. J. Hum. Genet. 2016;61: 705-709. DOI 10.1038/jhg.2016.33.

15. Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alföldi J., Wang Q., Collins R.L., Laricchia K.M., Ganna A., Birnbaum D.P., Gauthier L.D., Brand H., Solomonson M., Watts N.A., Rhodes D., Singer-Berk M., England E.M., Seaby E.G., Kosmicki J.A., Walters R.K., Tashman K., Farjoun Y., Banks E., Poterba T., Wang A., Seed C., Whiffin N., Chong J.X., Samocha K.E., Pierce-Hoffman E., Zappala Z., O’Donnell-Luria A.H., Minikel E.V., Weisburd B., Lek M., Ware J.S., Vittal C., Armean I.M., Bergelson L., Cibulskis K., Connolly K.M., Covarrubias M., Donnelly S., Ferriera S., Gabriel S., Gentry J., Gupta N., Jeandet T., Kaplan D., Llanwarne C., Munshi R., Novod S., Petrillo N., Roazen D., Ruano-Rubio V., Saltzman A., Schleicher M., Soto J., Tibbetts K., Tolonen C., Wade G., Talkowski M.E.; The Genome Aggregation Database Consortium, Neale B.M., Daly M.J., MacArthur D.G. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. 2019;531210. https://doi.org/10.1101/531210.

16. Lachance C.H. Practical aspects of monogenic diabetes: A clinical point of view. Can. J. Diabetes. 2016;40(5):368-375. DOI 10.1016/j.jcjd.2015.11.004.

17. Landrum M.J., Lee J.M., Benson M., Brown G.R., Chao C., Chitipiralla S., Gu B., Hart J., Hoffman D., Jang W., Karapetyan K., Katz K., Liu C., Maddipatla Z., Malheiro A., McDaniel K., Ovetsky M., Riley G., Zhou G., Holmes J.B., Kattman B.L., Maglott D.R. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062-D1067. DOI 10.1093/nar/gkx1153.

18. Li H., Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25(14):1754-1760. DOI 10.1093/bioinformatics/btp324.

19. Lorini R., Klersy C., d’Annunzio G., Massa O., Minuto N., Iafusco D., Bellannè-Chantelot C., Frongia A.P., Toni S., Meschi F., Cerutti F., Barbetti F.; Italian Society of Pediatric Endocrinology and Diabetology (ISPED) Study Group. Maturity-onset diabetes of the young in children with incidental hyperglycemia : amulticenter Italian study of 172 families. Diabetes Care. 2009;32(10):1864-1866. DOI 10.2337/dc08-2018.

20. Ma S.L., Vega-Warner V., Gillies C., Sampson M.G., Kher V., Sethi S.K., Otto E.A. Whole exome sequencing reveals novel PHEX splice site mutations in patients with Hypophosphatemic rickets. PLoS One. 2015;10(6):e0130729. DOI 10.1371/journal.pone.0130729.

21. Matschinsky F., Liang Y., Kesavan P., Wang L., Froguel P., Velho G., Cohen D., Permutt M.A., Tanizawa Y., Jetton T.L. Glucokinase as pancreatic cell glucose sensor and diabetes gene. J. Clin. Invest. 1993;92(5):2092-2098. DOI 10.1172/JCI116809.

22. McDonald T.J., Ellard S. Maturity onset diabetes of the young: Identification and diagnosis. Ann. Clin. Biochem. 2013;50:403-415. DOI 10.1177/0004563213483458.

23. McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303. DOI 10.1101/gr.107524.110.

24. Osbak K.K., Colclough K., Saint-Martin C., Beer N.L., Bellanné-Chantelot C., Ellard S., Gloyn A.L. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum. Mutat. 2009;30:1512-1526. DOI 10.1002/humu.21110.

25. Ovsyannikova A.K., Rymar O.D., Shakhtshneider E.V., Klimontov V.V., Koroleva E.A., Myakina N.E., Voevoda M.I. ABCC8-related maturity-onset diabetes of the young (MODY12): clinical features and treatment perspective. Diabetes Ther. 2016;7(3):591-600. DOI 10.1007/s13300-016-0192-9.

26. Plengvidhya N., Boonyasrisawat W., Chongjaroen N., Jungtrakoon P., Sriussadaporn S., Vannaseang S., Banchuin N., Yenchitsomanus P.T. Mutations of maturity-onset diabetes of the young (MODY) genes in Thais with early-onset type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.). 2009;70(6):847-853. DOI 10.1111/j.1365-2265.2008.03397.x.

27. Pruhova S., Dusatkova P., Kraml P.J., Kulich M., Prochazkova Z., Broz J., Zikmund J., Cinek O., Andel M., Pedersen O., Hansen T., Leb J. Chronic mild hyperglycemia in GCK-MODY patients does not increase carotid intima-media thickness. Int. J. Endocrinol. 2013;2013:718254. DOI 10.1155/2013/718254.

28. Sambrook J., Russell D.W. Purification of nucleic acids by extraction with phenol:chloroform. Cold Spring Harbor Protoc. 2006;2006(1): 4455. DOI 10.1101/pdb.prot4455.

29. Shakhtshneider E.V., Ivanoshchuk D.Е., Makarenkova К.V., Orlov P.S., Timoshchenko О.V., Bazhan S.S., Nikitin Yu.P., Voevoda М.I. Cascade genetic screening in diagnostics of heterozygous familial hypercholesterolemia: clinical case. Russ. J. Cardiol. 2017;6(1460): 178-179. http://dx.doi.org/10.15829/1560-4071-2017-6-178-179. (in Russian)

30. Shields B.M., Hicks S., Shepherd M.H., Colclough K., Hattersley A.T., Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504-2508. DOI 10.1007/s00125-010-1799-4.

31. Slaugenhaupt S.A., Blumenfeld A., Gill S.P., Leyne M., Mull J., Cuajungco M.P., Liebert C.B., Chadwick B., Idelson M., Reznik L., Robbins C., Makalowska I., Brownstein M., Krappmann D., Scheidereit C., Maayan C., Axelrod F.B., Gusella J.F. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am. J. Hum. Genet. 2001;68(3):598-605. DOI 10.1086/318810.

32. Spyer G., Macleod K.M., Shepherd M., Ellard S., Hattersley A.T. Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet. Med. 2009;26(1):14-18. DOI 10.1111/j.1464-5491.2008.02622.x.

33. Steele A.M., Shields B.M., Wensley K.J., Colclough K., Ellard S., Hattersley A.T. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3):279-286. DOI 10.1001/jama.2013.283980.

34. Stenson P.D., Mort M., Ball E.V., Evans K., Hayden M., Heywood S., Hussain M., Phillips A.D., Cooper D.N. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum. Genet. 2017;136(6):665-677. DOI 10.1007/s00439-017-1779-6.

35. Stride A., Vaxillaire M., Tuomi T., Barbetti F., Njølstad P.R., Hansen T., Costa A., Conget I., Pedersen O., Søvik O., Lorini R., Groop L., Froguel P., Hattersley A.T. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002; 45(3):427-435. DOI 10.1007/s00125-001-0770-9.

36. Thanabalasingham G., Owen K.R. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ. 2011;343:d6044. DOI 10.1136/bmj.d6044.

37. The 1000 Genomes Project Consortium, Auton A., Brooks L.D., Durbin R.M., Garrison E.P., Kang H.M., Korbel J.O., Marchini J.L., McCarthy S., McVean G.A., Abecasis G.R.A global reference for human genetic variation. Nature. 2015;526(7571):68-74. DOI 10.1038/nature15393.

38. Toaima D., Näke A., Wendenburg J., Praedicow K., Rohayem J., Engel K., Galler A., Gahr M., Lee-Kirsch M.A. Identification of novel GCK and HNF1A/TCF1 mutations and polymorphisms in German families with maturity-onset diabetes of the young (MODY). Hum. Mutat. 2005;25(5):503-504. DOI 10.1002/humu.9334.

39. Wang K., Li M., Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. DOI 10.1093/nar/gkq603.

40. Wędrychowicz A., Tobór E., Wilk M., Ziółkowska-Ledwith E., Rams A., Wzorek K., Sabal B., Stelmach M., Starzyk J.B. Phenotype Heterogeneity in glucokinase-maturity-onset diabetes of the young (GCK-MODY) patients. J. Clin. Res. Pediatr. Endocrinol. 2017; 9(3):246-252. DOI 10.4274/jcrpe.4461.

41. Xiong H.Y., Alipanahi B., Lee L.J., Bretschneider H., Merico D., Yuen R.K., Hua Y., Gueroussov S., Najafabadi H.S., Hughes T.R., Morris Q., Barash Y., Krainer A.R., Jojic N., Scherer S.W., Blencowe B.J., Frey B.J. The human splicing code reveals new insights into the genetic determinants of disease. Science. 2015;347(6218): 1254806. DOI 10.1126/science.1254806.